Special Encore: U.S. Pharmaceuticals - The Fu...

Our Chief Fixed Income Strategist Vishy Tirupattur and U.S. Head of Credit Strategy Vishwas Patkar discuss the implications of private credit’s exposure to the software industry.Read more insights from Morgan Stanley.----- Transcript -----Vishy Tirupattur: Welcome to Thoughts on ...  Show more

Our Deputy Head of Global Research Michael Zezas and Stephen Byrd, Global Head of Thematic and Sustainability Research, discuss how the U.S. is positioning AI as a pillar of geopolitical influence and what that means for nations and investors.Read more insights from Morgan Stanle ...  Show more

with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)

The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, M ...

Mapping the human genome led to big advances in diagnosing rare disease. But diagnosis is only the first step in dealing with an illness. So what do you do if your child is found to have a condition that has no treatment? We hear from Michelle Teng, a mother who co-founded a biot ...  Show more

with Vas Narasimhan (@vasnarasimhan), Jorge Conde (@jorgecondebio), Vijay Pande (@vijaypande), and Sonal Chokshi (@smc90)

On average, only 1 out of 20 medicines works when we actually bring them into the human body, and these rates of success haven't moved much in the ph ...

Speaking with the CEO and founder of a pharmaceutical company was an incredible experience. William Stilley knows the science inside and out. And, he is able to explain it clearly, in understandable terms. What makes Adial different from many of the well-known drug companies is t ...  Show more